Cargando…

Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12–15 years: Interim analysis of a large community-randomized controlled trial

This community-randomized controlled trial was initiated to assess the overall and herd effects of 2 different human papillomavirus (HPV) immunization strategies in over 80,000 girls and boys aged 12–15 y in 33 communities in Finland (ClinicalTrials.gov NCT00534638). Overall, 14,838 adolescents rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lehtinen, Matti, Eriksson, Tiina, Apter, Dan, Hokkanen, Mari, Natunen, Kari, Paavonen, Jorma, Pukkala, Eero, Angelo, Maria-Genalin, Zima, Julia, David, Marie-Pierre, Datta, Sanjoy, Bi, Dan, Struyf, Frank, Dubin, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215585/ https://www.ncbi.nlm.nih.gov/pubmed/27841725 http://dx.doi.org/10.1080/21645515.2016.1183847

Ejemplares similares

Effectiveness of various human papillomavirus vaccination strategies: A community randomized trial in Finland
por: Lehtinen, Matti, et al.
Publicado: (2021)

Safety of the AS04-adjuvanted human papillomavirus (HPV)-16/18 vaccine in adolescents aged 12–15 years: end-of-study results from a community-randomized study up to 6.5 years
por: Bi, Dan, et al.
Publicado: (2019)

Effectiveness of the AS04‐adjuvanted HPV‐16/18 vaccine in reducing oropharyngeal HPV infections in young females—Results from a community‐randomized trial
por: Lehtinen, Matti, et al.
Publicado: (2019)

Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials
por: Lehtinen, Matti, et al.
Publicado: (2017)

Vaccination With Moderate Coverage Eradicates Oncogenic Human Papillomaviruses If a Gender-Neutral Strategy Is Applied
por: Vänskä, Simopekka, et al.
Publicado: (2020)

Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme
por: Angelo, Maria-Genalin, et al.
Publicado: (2014)

The Prevalence of HSV, HHV-6, HPV and Mycoplasma genitalium in Chlamydia trachomatis positive and Chlamydia trachomatis Negative Urogenital Samples among Young Women in Finland
por: Korhonen, Suvi, et al.
Publicado: (2019)

Human papillomavirus vaccine efficacy against invasive, HPV-positive cancers: population-based follow-up of a cluster-randomised trial
por: Lehtinen, Matti, et al.
Publicado: (2021)

Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study
por: Namujju, Proscovia B, et al.
Publicado: (2014)

Cancer Registry follow‐up for 17 million person‐years of a nationwide maternity cohort
por: Lehtinen, Matti, et al.
Publicado: (2017)

Association of Chlamydia trachomatis infection with cervical atypia in adolescent women with short-term or long-term use of oral contraceptives: a longitudinal study in HPV vaccinated women
por: Adhikari, Indira, et al.
Publicado: (2022)

Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience
por: Angelo, Maria-Genalin, et al.
Publicado: (2014)

Aspects of Prophylactic Vaccination against Cervical Cancer and Other Human Papillomavirus-Related Cancers in Developing Countries
por: Natunen, Kari, et al.
Publicado: (2011)

Is the risk of cervical atypia associated with the interval between menarche and the start of sexual activity? A population-based cohort study
por: Adhikari, Indira, et al.
Publicado: (2019)

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post‐hoc analysis from a randomized controlled trial
por: Garland, Suzanne M., et al.
Publicado: (2016)

Immunopathogenesis of Chlamydial Pelvic Inflammatory Disease: The Role of Heat-Shock Proteins
por: Paavonen, Jorma, et al.
Publicado: (1994)

Sound efficacy of prophylactic HPV vaccination: Basics and implications
por: Lehtinen, Matti, et al.
Publicado: (2012)

Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom
por: Willame, Corinne, et al.
Publicado: (2016)

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
por: Szarewski, Anne, et al.
Publicado: (2013)

Oral contraceptive use before first birth and risk of breast cancer: a case control study
por: Hemminki, Elina, et al.
Publicado: (2002)

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial
por: Zhu, Feng-Cai, et al.
Publicado: (2011)

Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA
por: Castellsagué, Xavier, et al.
Publicado: (2014)

Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses( )
por: Arroyo Mühr, Laila Sara, et al.
Publicado: (2022)

Impact of Vaccination on 14 High-Risk HPV Type Infections: A Mathematical Modelling Approach
por: Vänskä, Simopekka, et al.
Publicado: (2013)

Women and vaccinations: From smallpox to the future, a tribute to a partnership benefiting humanity for over 200 years
por: Datta, Sanjoy, et al.
Publicado: (2009)

Moral dilemma(s) in human papillomavirus vaccination – revisiting the role of the herd effect
por: Lehtinen, Matti, et al.
Publicado: (2021)

Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2019)

A population-based study on the risk of cervical cancer and cervical intraepithelial neoplasia among grand multiparous women in Finland
por: Hinkula, M, et al.
Publicado: (2004)

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials
por: Zhu, Fengcai, et al.
Publicado: (2014)

Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study
por: Folschweiller, Nicolas, et al.
Publicado: (2020)

Erratum to: Prevalence and Incidence of Human Papillomavirus (HPV) Infection Before and After Pregnancy: Pooled Analysis of the Control Arms of Efficacy Trials of HPV-16/18 AS04-Adjuvanted Vaccine
por: Chen, Jing, et al.
Publicado: (2020)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial
por: Gray, Penelope, et al.
Publicado: (2021)

A discrepancy of Chlamydia trachomatis incidence and prevalence trends in Finland 1983–2003
por: Lyytikäinen, Erika, et al.
Publicado: (2008)

Detection of Human Papillomavirus DNA by AffiProbe HPV-DNA Test Kit in Cervical Scrapes or Biopsies-Histopathologic Correlates
por: Nieminen, Pekka, et al.
Publicado: (1994)

Meta‐analysis of the risk of autoimmune thyroiditis, Guillain‐Barré syndrome, and inflammatory bowel disease following vaccination with AS04‐adjuvanted human papillomavirus 16/18 vaccine
por: Rosillon, Dominique, et al.
Publicado: (2020)

Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18–45 years: Follow-up through Month 48 in a Phase III randomized study
por: Einstein, Mark H, et al.
Publicado: (2014)

Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland
por: French, K M, et al.
Publicado: (2007)

Human Papillomavirus Genotype Replacement: Still Too Early to Tell?
por: Man, Irene, et al.
Publicado: (2020)

Cohort profile: a nationwide cohort of Finnish military recruits born in 1958 to study the impact of lifestyle factors in early adulthood on disease outcomes
por: Sormunen, Jorma, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_plum6jntvc0s87h0tcpgaii4s1